Research Reports Initiation on Medical Equipment Stocks -- Masimo, NovoCure, Nxstage Medical, and Varex Imaging

Monday, May 22, 2017 Research News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, May 22, 2017 /PRNewswire/ --

On Friday, May 19, 2017, US markets saw broad

based gains with all nine sectors finishing the trading sessions in green. Major US indices were also bullish at the close of last Friday's session. The NASDAQ Composite ended the day at 6,083.70, up 0.47%; the Dow Jones Industrial Average edged 0.69%
higher, to finish at 20,804.84; and the S&P 500 closed at 2,381.73, up 0.68%. This Monday morning, looks at the performance of these four Medical Appliances & Equipment stocks: Masimo Corp. (NASDAQ: MASI), NovoCure Ltd (NASDAQ: NVCR), Nxstage Medical Inc. (NASDAQ: NXTM), and Varex Imaging Corp. (NASDAQ: VREX). You can access our complimentary research reports on these stocks now at:


Irvine, California headquartered Masimo Corp.'s stock finished last Friday's session 0.92% higher at $85.67. A total volume of 489,756 shares was traded. The Company's shares have advanced 1.85% over the previous three months and 27.11% since the start of this year. The stock is trading above its 200-day moving average by 18.06%. Additionally, shares of Masimo, which develops, manufactures, and markets noninvasive monitoring technologies worldwide, have a Relative Strength Index (RSI) of 35.23. Visit us today and download your complete report on MASI for free at:


On Friday, shares in Saint Helier, the Channel Islands-based NovoCure Ltd ended the session 2.21% higher at $11.55. The stock recorded a trading volume of 362,541 shares. The Company's shares have gained 50.00% in the previous three months and 47.13% on an YTD basis. The stock is trading 15.94% above its 50-day moving average and 38.33% above its 200-day moving average. Moreover, shares of NovoCure, which engages in the development, manufacture, and commercialization of tumor treating fields for the treatment of solid tumors, have an RSI of 56.53. The complimentary research report on NVCR can be accessed at:

Nxstage Medical  

Lawrence, Massachusetts headquartered Nxstage Medical Inc.'s shares gained 1.47%, closing the session at $21.40 with a total trading volume of 467,971 shares. The stock is trading 16.78% below its 200-day moving average. Shares of the Company, which develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure, have an RSI of 25.50.

On May 04th, 2017, research firm Northland Capital downgraded the Company's stock rating from 'Outperform' to 'Market Perform'. Register for free on and download the PDF research report on NXTM at:

Varex Imaging  

Last Friday at the close, shares in Salt Lake City, Utah headquartered Varex Imaging Corp. recorded a trading volume of 119,505 shares. The stock ended the session 0.47% lower at $34.22. The Company's shares have advanced 4.71% over the previous three months and 26.74% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 3.21% and 5.98%, respectively. Furthermore, shares of Varex Imaging, which designs and manufactures medical X-ray tubes and image processing solutions, have an RSI of 55.94. Get free access to your research report on VREX at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store